Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation.
about
The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients.Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine.Morbidity and mortality of cardiac surgery following renal transplantation.The role of tacrolimus in renal transplantation.Multivessel coronary revascularization and outcomes in kidney transplant recipients.Cell Therapy in Kidney Transplantation: Focus on Regulatory T Cells.Efficacy and safety of tacrolimus compared with ciclosporin-A in renal transplantation: 7-year observational results.Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study.Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly.Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results.Impact of tacrolimus and mycophenolate mofetil regimen vs. a conventional therapy with steroids on cardiovascular risk in liver transplant patients.Traditional and nontraditional cardiovascular risk factors and estimated risk for coronary artery disease in renal transplant recipients: a single-center experience.Validity of cardiovascular risk prediction models in kidney transplant recipients.Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation.Early Subclinical Coronary Artery Calcification in Young Adults Who Were Pediatric Kidney Transplant Recipients
P2860
Q35612903-CA151F49-9F43-4946-8AE4-72851DA4BE85Q36073213-706C4EA8-3CCD-40F7-8C1D-04B6A05CF5B1Q36473128-658512C4-C469-4264-AA07-07C840104079Q37099023-9708AE46-DFD8-424C-B6E6-0690492B0BCBQ37277273-941358AA-2B8F-44C7-A669-961EA258100DQ39279238-2A93FB2D-CF96-4FBF-B2FB-CD5335E59C40Q40325148-912731A0-9D8B-4715-B8A9-6F104980A9F7Q44136852-8410ADCF-8F07-4722-9D14-2966A1A20800Q45291387-78FA579C-2F76-4319-BECA-56CB311D76DFQ46021679-3602A564-0216-44F4-8284-7EE428481459Q46765559-6F0129DA-5463-4E4D-807D-A7214C48399BQ50446755-D955CD50-C41B-41C7-9D09-C2430587715EQ53088029-0320DB9D-390A-4542-AB38-238C3A6E402EQ53148108-D92A16FE-C2FB-4310-BB93-8DC7CFB33F37Q53629903-9E2ED9B6-6644-4E89-B7BA-4D94103E6804Q57907909-2B623804-C9E6-4B60-AE30-C2163EE47D6F
P2860
Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Cardiovascular risk factors an ...... tors in renal transplantation.
@en
Cardiovascular risk factors an ...... tors in renal transplantation.
@nl
type
label
Cardiovascular risk factors an ...... tors in renal transplantation.
@en
Cardiovascular risk factors an ...... tors in renal transplantation.
@nl
prefLabel
Cardiovascular risk factors an ...... tors in renal transplantation.
@en
Cardiovascular risk factors an ...... tors in renal transplantation.
@nl
P2093
P2860
P1476
Cardiovascular risk factors an ...... tors in renal transplantation.
@en
P2093
Bernhard K Krämer
Carl Zülke
Christian Hengstenberg
Christian Schmidt
European Tacrolimus vs. Cyclosporine Microemulsion Renal Transplantation Study Group
Jörg Marienhagen
Martin C Kammerl
Michael Fischereder
P2860
P304
P356
10.1034/J.1600-6143.2003.00156.X
P407
P577
2003-08-01T00:00:00Z